arrow
K

Kevin M. Tuffy

AstraZeneca
H指数:12
被引数:1,058

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High Conservation of the Human Metapneumovirus Fusion Protein in Contemporary Global Sequences Supports Its Continued Relevance for Therapeutic and Prophylactic Consideration

人类副黏病毒融合蛋白在当代全球序列中的高度保守性支持其持续作为治疗和预防考虑的重要性

2026-10-050
OA
Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape

针对SARS-CoV-2变体广泛中和及抗病毒逃逸的临床抗体前瞻性优化

2025-03-280
OA
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials (Vol 14, 4347, 2023)
2024-04-080
OAAI
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

两项nirsevimab随机临床试验中婴儿RSV感染的分子和表型特征

2023-07-1922
OAAI
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
2023-07-0135
PRE
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants

PROVENT预防试验中的突破性SARS-CoV-2感染与AZD7442 (Tixagevimab/Cilgavimab) 耐药变体无关

2023-06-062
OAAI
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
2022-03-09167
OAAI